FpC - Rockwell Medical pops 6% on licensing deal for Triferic AVNU in Turkey
Rockwell Medical (RMTI) perks up 6% premarket after entering into an exclusive license agreement with Drogsan Pharmaceuticals for the rights to commercialize Triferic AVNU (ferric pyrophosphate citrate injection) in Turkey. Under the terms of the license agreement, Drogsan will be the exclusive development and commercialization partner for Triferic in Turkey and Rockwell Medical will supply the product to Drogsan.The agreement also allows for Drogsan to negotiate further geographic expansion into the surrounding region.In consideration, Rockwell Medical will receive an upfront fee and will be eligible for milestone payments based on reimbursement price approval.
For further details see:
Rockwell Medical pops 6% on licensing deal for Triferic AVNU in Turkey